Key points are not available for this paper at this time.
Design
Editorial
Highlights the growing need for cardio-oncology collaboration in China due to increasing cancer survivorship and associated cardiovascular toxicities.
![Figure][1] ![Figure][1] The number of cancer patients and survivors is increasing in China. However, many cancer therapies have short- and long-term cardiovascular (CV) toxicities. The risk of cardiovascular disease (CVD) in cancer patients is substantially higher than the
No takes yet. Share an insight, caveat, or question.
Xia et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: